tiprankstipranks
Advertisement
Advertisement

AU:PER Stock Latest News

Percheron Therapeutics Launches Discounted Entitlement Offer, Excludes Overseas Holders
Company AnnouncementsPercheron Therapeutics Launches Discounted Entitlement Offer, Excludes Overseas Holders
21h ago
Percheron Therapeutics Launches Non-Renounceable Entitlement Offer With Free-Attaching Options
PremiumCompany Announcements
Percheron Therapeutics Launches Non-Renounceable Entitlement Offer With Free-Attaching Options
21h ago
Percheron Therapeutics Launches Discounted Entitlement and Shortfall Offer
PremiumCompany Announcements
Percheron Therapeutics Launches Discounted Entitlement and Shortfall Offer
9d ago
Percheron Therapeutics Plans Issue of 50 Million Unquoted Options
PremiumCompany Announcements
Percheron Therapeutics Plans Issue of 50 Million Unquoted Options
9d ago
Percheron Therapeutics Plans Large Pro Rata Capital Raising on ASX
PremiumCompany Announcements
Percheron Therapeutics Plans Large Pro Rata Capital Raising on ASX
9d ago
Percheron Updates Timetable for $2.2m Entitlement Offer Ahead of 2026 Trials
PremiumCompany AnnouncementsPercheron Updates Timetable for $2.2m Entitlement Offer Ahead of 2026 Trials
9d ago
Percheron Therapeutics Launches Pro Rata Rights Offer at Discounted Issue Price
Premium
Company Announcements
Percheron Therapeutics Launches Pro Rata Rights Offer at Discounted Issue Price
9d ago
Percheron Therapeutics Launches Discounted Entitlement Offer to Fund HMBD-002 Trial
Premium
Company Announcements
Percheron Therapeutics Launches Discounted Entitlement Offer to Fund HMBD-002 Trial
9d ago
Percheron Therapeutics Plans Issue of 13.75 Million Unquoted Options
PremiumCompany Announcements
Percheron Therapeutics Plans Issue of 13.75 Million Unquoted Options
11d ago
Percheron Therapeutics Narrows Half-Year Loss but Sees Net Assets Per Share Fall
PremiumCompany Announcements
Percheron Therapeutics Narrows Half-Year Loss but Sees Net Assets Per Share Fall
27d ago
Percheron Advances HMBD-002 into Innovative Phase II After Positive Phase I Cancer Data
PremiumCompany Announcements
Percheron Advances HMBD-002 into Innovative Phase II After Positive Phase I Cancer Data
2M ago
Percheron Therapeutics Director Increases On-Market Shareholding
PremiumCompany Announcements
Percheron Therapeutics Director Increases On-Market Shareholding
3M ago
Percheron Therapeutics Director James Garner Increases Shareholding via On-Market Purchase
PremiumCompany AnnouncementsPercheron Therapeutics Director James Garner Increases Shareholding via On-Market Purchase
3M ago
Percheron Therapeutics Updates Corporate Presentation with New Program Insights
Premium
Company Announcements
Percheron Therapeutics Updates Corporate Presentation with New Program Insights
5M ago
Percheron Therapeutics Advances HMBD-002 with Positive Trial Results
Premium
Company Announcements
Percheron Therapeutics Advances HMBD-002 with Positive Trial Results
5M ago
Percheron Therapeutics Reports Strong Shareholder Support at AGM
PremiumCompany Announcements
Percheron Therapeutics Reports Strong Shareholder Support at AGM
5M ago
Percheron Therapeutics Unveils Future Plans at AGM
PremiumCompany Announcements
Percheron Therapeutics Unveils Future Plans at AGM
5M ago
Percheron Therapeutics Releases Final Results of Phase I Clinical Trial for HMBD-002
PremiumCompany Announcements
Percheron Therapeutics Releases Final Results of Phase I Clinical Trial for HMBD-002
6M ago
Percheron Therapeutics Advances HMBD-002 Cancer Therapy Development
PremiumCompany Announcements
Percheron Therapeutics Advances HMBD-002 Cancer Therapy Development
6M ago
Percheron Therapeutics Strengthens Leadership Team to Advance Cancer Therapy
PremiumCompany AnnouncementsPercheron Therapeutics Strengthens Leadership Team to Advance Cancer Therapy
6M ago
Percheron Therapeutics Announces 2025 Annual General Meeting
Premium
Company Announcements
Percheron Therapeutics Announces 2025 Annual General Meeting
6M ago
Percheron Therapeutics Secures $1.43 Million R&D Rebate to Advance Oncology Program
Premium
Company Announcements
Percheron Therapeutics Secures $1.43 Million R&D Rebate to Advance Oncology Program
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >